In the original article [1], there was a mistake in Table 1 as published. There were two tumors with tumor size ≤ 5 cm in the NTRK fusion group (n = 5); however, there were three tumors with tumor size ≤ 5 cm in the five cases in Table 3. Moreover, patients 0 and 1 were low- and intermediate-risk of metastasis, respectively, in Table 1, which was not consistent with the results in Table 3. The corrected Table 1 appears below. Modified numbers are red-colored.
Table 1.
Baseline characteristics.
| Characteristics | Total (n = 31) N (%) | NTRK Fusion (n = 5) | NTRK Wild Type (n = 26) | p-Value |
|---|---|---|---|---|
| Age | ||||
| Median (range) | 56 (33–92) | 61 (33–92) | 53 (37–84) | 0.163 |
| Sex | - | - | - | 1000 |
| Male | 14 (45.2) | 2 (40.0) | 12 (46.2) | - |
| Female | 17 (54.8) | 3 (60.0) | 14 (53.8) | - |
| Tumor size (cm) | - | - | - | - |
| Median ± SD | 8.2 ± 5.3 | 3.9 ± 6.5 | 6.0 ± 5.2 | 0.410 |
| Tumor location | - | - | - | 0.028 |
| Abdominal wall | 1 (0.3) | 0 (0.0) | 1 (3.8) | - |
| Stomach | 14 (45.1) | 1 (20.0) | 14 (53.8) | - |
| Small bowel | 11 (35.4) | 2 (40.0) | 6 (23.1) | - |
| Descending colon | 1 (0.3) | 0 (0.0) | 1 (3.8) | - |
| Rectum | 4 (12.9) | 2 (40.0) | 4 (15.4) | - |
| Tumor size, groups (cm) ◇ | - | - | - | 1000 |
| ≤5 | 14 (50.0) | 3 (60.0) | 11 (47.8) | - |
| >5 | 14 (50.0) | 2 (40.0) | 12 (52.2) | -- |
| Mitotic rate ◐ (no. of mitoses/50 HPFs *) | - | - | - | 0.711 |
| ≤5 | 11 (50.0) | 2 (40.0) | 12 (52.2) | - |
| >5 | 16 (50.0) | 3 (60.0) | 10 (43.5) | - |
| Disease status | - | - | - | 0.859 |
| No evidence of disease | 21 (67.7) | 5 (100.0) | 16 (61.5) | - |
| on anticancer treatment | 3 (9.7) | 0 (0.0) | 3 (11.5) | - |
| Unknown | 3 (9.7) | 0 (0.0) | 3 (11.5) | - |
| Dead | 4 (12.9) | 0 (0.0) | 4 (15.4) | - |
| Risk of metastasis ◈ | - | - | - | 0.253 |
| Low | 8 (25.8) | 1 (20.0) | 7 (26.9) | - |
| Intermediate | 3 (9.7) | 0 (0.0) | 3 (11.5) | - |
| High | 17 (54.8) | 4 (80.0) | 13 (50.0) | - |
| Not assessable | 3 (9.7) | 0 (0.0) | 3 (11.5) | - |
| Surgical treatment | - | - | - | 1000 |
| Yes | 28 (90.3) | 5 (100.0) | 23 (88.5) | - |
| No | 3 (9.7) | 0 (0.0) | 3 (11.5) | - |
◇ For three inoperable cases, size information and mitotic rate are missing because there was no surgical specimen. ◐ Mitotic rate was not evaluated in one surgical specimen. ◈ Risk of metastasis was evaluated according to the National Institute of Health (NIH) classification. HPFs: high-power fields; * per 50 HPFs is a total of 5 mm2.
The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. The original publication has also been updated.
Footnotes
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Reference
- 1.Lee J.H., Shin S.-J., Choe E.-A., Kim J., Hyung W.J., Kim H.S., Jung M., Beom S.-H., Kim T.I., Ahn J.B., et al. Tropomyosin-related kinase fusions in gastrointestinal stromal tumors. Cancers. 2022;14:2659. doi: 10.3390/cancers14112659. [DOI] [PMC free article] [PubMed] [Google Scholar]